Page of

Biologics in paediatric rheumatic diseases 

Biologics in paediatric rheumatic diseases
Chapter:
Biologics in paediatric rheumatic diseases
Source:
Oxford Textbook of Rheumatology (4 ed.)
Author(s):

Daniel J. Lovell

, Nicolino Ruperto

, Hermine I. Brunner

, and Alberto Martini

DOI:
10.1093/med/9780199642489.003.0084_update_003
Previous versions of this chapter are available. To view earlier versions of this chapter view the full site here.

The introduction of biological therapies into the treatment of children with rheumatic diseases has dramatically changed our expectation about treatment goals in children with a wide variety of forms of chronic arthritis. The outcomes of these children have been dramatically improved. The application of biological therapies to other paediatric rheumatic diseases has been much more limited and a change in treatment of these other rheumatic diseases has been less impacted by the introduction of biological therapies. The overall safety profile of biological therapies in children reveal issues that are similar to those in adults both in the frequency and types of toxicities. The paediatric-specific safety issues are childhood vaccinations and varicella. Biologic therapies have been included in recently developed validated treatment guidelines for juvenile idiopathic arthritis (JIA). Biologic therapies for children with rheumatic diseases have advanced greatly in the last decade and many exciting studies are ongoing and in development.

Sign In

Copyright © 2020. All rights reserved.